[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia-vt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia-vt":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,52,83,103,130,154,175,197,227,253,275,294,318,347],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100570149","safety-and-performance-assessment-of-the-sphere-9-catheter-and-affera-ablation-system-for-the-treatment-of-ventricular-tachycardia-sphere-9-vt-efs-100570149",false,"NCT06703489","Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)","Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia","Inclusion Criteria:\n\n1. Any of the following:\n\n   1. Ischemic cardiomyopathy (ICM) patients with prior history of myocardial infarction (MI).\n   2. Non-ischemic cardiomyopathy (NICM) patients with documented myocardial scar in a territory without coronary stenosis as evidenced by cardiac imaging.\n2. At least one episode of sustained (continuous for \\>30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.\n3. Recurrence of sustained ventricular tachycardia despite class I or III antiarrhythmic drug therapy or ICD intervention.\n4. Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 3 months prior to the ablation procedure.\n5. Age 18 through 85 years old.\n6. Willing and able to provide informed consent.\n7. Willing and able to comply with all pre-, post-, and follow-up testing requirements.\n\nExclusion Criteria:\n\n1. Incessant VT necessitating hemodynamic support prior to the ablation procedure.\n2. Unstable polymorphic VT or ventricular fibrillation (VF).\n3. VTs due to any of the following:\n\n   1. Idiopathic VT\n   2. Automaticity or triggered activity\n   3. Lamin or titin genetic mutation\n   4. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug induced arrhythmia).\n4. NICM subjects with active inflammatory processes (e.g., myocarditis) within 120 days prior to the ablation procedure.\n5. VT or VF thought to be from channelopathies.\n6. More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.\n7. Sarcoidosis.\n8. Hypertrophic cardiomyopathy, except when due to an apical aneurysm.\n9. Unstable angina.\n10. Active myocardial ischemia.\n11. Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.\n12. Any percutaneous coronary intervention within 2 months (60 days) prior to the ablation procedure.\n13. Any cardiac surgery within 3 months (90 days) prior to the ablation procedure.\n14. Left ventricular ejection fraction (LVEF) \\\u003C15%.\n15. NYHA Class IV heart failure.\n16. Decompensated heart failure.\n17. Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).\n18. Ventricular assist device (VAD) implanted, planned or required for the procedure.\n19. Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.\n20. Presence of prosthetic valve in the aortic or mitral valve.\n21. Patients with advanced COPD (on home oxygen).\n22. Presence of intracardiac thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.\n23. Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.\n24. Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.\n25. Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count \\\u003C80,000).\n26. Contraindication to anticoagulation.\n27. End-stage renal disease (requiring dialysis).\n28. Acute illness, active infection, or sepsis.\n29. Life expectancy less than 12 months.\n30. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.\n31. Body mass index \\>45 kg\u002Fm2.\n32. Known ongoing drug or alcohol dependency.\n33. Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.\n34. Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).\n35. Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.","ALL","18 Years","85 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.",[27],"Ventricular Tachycardia (VT)",[29,30,31,32,33,34,35,36,37,38],"Recurrent sustained monomorphic ventricular tachycardia","Monomorphic ventricular tachycardia","Ventricular tachycardia","Arrhythmias, Cardiac","Heart Diseases","Cardiovascular Diseases","Pathologic Processes","Ischemic heart disease","Patient with Implantable Cardioverter Defibrillator (ICD)","Ischemic cardiomyopathy","RECRUITING","2026-06-15",{"date":42,"type":43},"2026-06-16","ACTUAL",{"date":45,"type":43},"2025-03-18",{"date":47,"type":21},"2027-01",{"name":49,"class":50},"Medtronic Cardiac Ablation Solutions","INDUSTRY",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100594859","complex-arrhythmia-registry-100594859","NCT07024927","Complex Arrhythmia Registry","Complex Arrhythmia Registry（CAR）： Long-term Outcomes of Catheter Ablation for Atrial Fibrillation or Ventricular Tachycardia： A Multicenter， Prospective Cohort Study","CAR","1. Atrial Fibrillation (AF) Cohort:\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).\n     3. Scheduled to undergo first-time catheter ablation for AF.\n     4. Procedure to be performed using a 3D mapping system.\n     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).\n     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).\n     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment\u002Fprocedure.\n     4. Severe active infection (e.g., septic shock, sepsis).\n     5. Contraindications to anticoagulation therapy.\n     6. Current participation in another interventional clinical trial that may confound the results of this study.\n     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.\n2. Ventricular Tachycardia (VT) Cohort\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:\n     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).\n     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).\n     5. Scheduled to undergo first-time catheter ablation for VT.\n     6. Procedure to be performed using a 3D mapping system.\n     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).\n     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).\n     3. Cardiac surgery within 60 days prior to the planned ablation procedure.\n     4. Severe coagulopathy (e.g., platelet count \\\u003C 50 x 10⁹\u002FL, disseminated intravascular coagulation (DIC)).\n     5. Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 20%.\n     6. Severe active infection (e.g., septic shock, sepsis).\n     7. Current participation in another interventional clinical trial that may confound the results of this study.\n     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.",{"count":61,"type":21},4000,"3 Years","OBSERVATIONAL","This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.",[66,27],"Atrial Fibrillation (AF)",[68,69,70,71],"atrial fibrillation","ventricular tachycardia","ablation","registry study","2026-06-02",{"date":74,"type":43},"2026-06-04",{"date":76,"type":43},"2025-10-21",{"date":78,"type":21},"2032-06",{"name":80,"class":81},"Beijing Anzhen Hospital","OTHER",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":82},"100573399","evolution-of-intracardiac-electrograms-recorded-by-left-bundle-branch-pacing-lead-in-patients-with-icd-or-crt-d-100573399","NCT06745778","Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D","Inclusion Criteria:\n\n* Patients aged \\>=18 yrs.\n* Patients indicated for ICD or CRT-D (primary or secondary prevention)\n* Patients who recently (\\\u003C=30 days) received ICD\u002FCRT-D implantation with LBBP\n* Patients' EGM can be digitally recorded\n* Patients are willing to participate in the study and provide signed informed consent\n\nExclusion Criteria:\n\n* Patients received CIED upgrade or replacement with old pacing leads\n* Patients are pregnant\n* Patients participate in another study that will confound this study",{"count":90,"type":21},50,"The goal of this observational study is to investigate the changes of LBB EGM during daily activities and overdrive pacing at the time of peri-implantation and up to 6-month follow-ups of ICD\u002FCRT-D patients. The main question it aims to answer is:\n\n• Does the LBBP lead can provide accurate, stable, and valid EGM for ICD\u002FCRT-D sensing and detection of ventricular tachyarrhythmia events? In each patient intracardiac EGMs of LBBP lead will be collected by ambulatory Holter monitor at the time of peri-implantation and up to 6-month follow-up. EGM collection will be collected at resting and walking conditions and overdrive pacing.",[27,93],"Ventricular Fibrillation","2026-05-06",{"date":96,"type":43},"2026-05-08",{"date":98,"type":43},"2025-02-26",{"date":100,"type":21},"2026-07-31",{"name":102,"class":50},"Medtronic Cardiac Rhythm and Heart Failure",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100637045","dynamic-voltage-mapping-to-personalise-the-ventricular-tachycardia-substrate-100637045","NCT07573579","Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate","DYNAMITE-VT","Inclusion Criteria:\n\n* Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies).\n* Willing and able to give informed consent for participation in the trial\n* Male or female aged between 18-85\n* Ischaemic and non-ischaemic cardiomyopathy\n* ICD insitu\n\nExclusion Criteria:\n\n* Unable or unwilling to consent\n* NYHA Class IV (end stage heart failure)\n* Metastatic cancer\n* End stage renal disease\n* Pregnant or breast feeding\n* Severe frailty",{"count":111,"type":21},40,[24],"Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart.\n\nPeople at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland.\n\nAn alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy.\n\nAlthough ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment.\n\nDynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation.\n\nIn this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.",[27],[116,117,118],"Catheter Ablation","Electroanatomical Mapping","Ventricular Tachycardia","NOT_YET_RECRUITING","2026-04-30",{"date":122,"type":43},"2026-05-07",{"date":124,"type":21},"2026-08-03",{"date":126,"type":21},"2029-08-01",{"name":128,"class":81},"Liverpool Heart and Chest Hospital NHS Foundation Trust",1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":139,"studyType":63,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":129},"100573303","cardiac-radiotherapy-for-ventricular-tachycardia-ii-100573303","NCT06744530","Cardiac RadiothErapy for VEntricular Tachycardia II","Cardiac RadiothErapy for VEntricular Tachycardia II - a Prospective Observational Cohort Study","CREVET II","Inclusion Criteria:\n\n* Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion\n* Ability to give a written informed consent and willingness to return for follow-up\n\nExclusion Criteria:\n\n* Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \\\u003C 6 months in the absence of VT\n* Any condition that is deemed a contraindication in the judgment of the investigators",{"count":90,"type":21},"4 Years","Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.",[27],[69,143,144],"STAR","Stereotactic radiotherapy","2026-04-28",{"date":147,"type":43},"2026-04-29",{"date":149,"type":43},"2025-01-01",{"date":151,"type":21},"2034-12",{"name":153,"class":81},"Universitaire Ziekenhuizen KU Leuven",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100631525","sympathetic-ablation-for-ventricular-arrhythmias-100631525","NCT07501819","Sympathetic Ablation for Ventricular Arrhythmias","Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias","Inclusion Criteria:\n\n1. Age 18 or older at the time of informed consent\n2. Willing and capable of providing written informed consent\n3. Implanted ICD or CRT-D\n4. Recurrent VT leading to ICD therapy (ATP or shock)\n5. Indicated for catheter ablation of VT per international guidelines\n6. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia\n\nExclusion Criteria:\n\n1. Contraindication to percutaneous femoral arterial access\n2. Heparin-induced thrombotic thrombocytopenia\n3. Prior surgical sympathectomy\n4. ECMO therapy in the past 30 days\n5. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)\n6. A most recently documented LVEF \\\u003C20% in the past 30 days\n7. Receiving inotropic drug therapy\n8. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment\n9. A life expectancy of less than 12 months according to physician judgment\n10. Involvement in any concurrent clinical study with an investigational therapy",{"count":162,"type":21},10,[24],"Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.",[27],"2026-03-24",{"date":168,"type":43},"2026-03-30",{"date":170,"type":21},"2026-04",{"date":172,"type":21},"2027-09",{"name":174,"class":50},"SymKardia",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":129},"100567523","non-invasive-programmed-stimulation-nips-to-guide-the-subsequent-vt-therapeutic-strategies-100567523","NCT06669299","Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","The Value of Late Non-Invasive Programmed Stimulation (NIPS) in the Setting of Ventricular Tachycardia (VT) Ablation to Guide the Subsequent VT Therapeutic Strategies: a Prospective Randomized Multicenter Study","Inclusion Criteria:\n\n* Patients with an implanted ICD (all brands)\n* Patients who underwent a successful (non-inducibility of any VT) Ventricular Tachycardia Ablation procedure, the \"index procedure\", supported by EnSite Precision or CARTO 3D mapping systems for the following etiologies: previous MI, myocarditis, ARVD, IDCM.\n* Induction of monomorphic VT at NIPS 3-7days after a successful index procedure\n* Age 18 years or more\n* Able to provide an informed consent to participate to the study and available to respect the assessments described in the protocol.\n\nExclusion Criteria:\n\n* Inducible VT after index procedure\n* Contraindication to anticoagulants\n* Presence of thrombi\n* Presence of Mitral and Aortic prosthetic valve\n* Recent (\\\u003C3 months) myocardial infarction or unstable angina or Coronary Artery Bypass\n* Pregnant or nursing\n* Ventricular Tachycardia caused by reversible pathology\n* \\\u003C 1 Year life expectancy according to the investigator",{"count":183,"type":21},51,[24],"The aim of this study is to define the importance of non-invasive programmed stimulation (NIPS) in risk stratification of ventricular tachycardia (VT) recurrence after catheter ablation and to determine the optimal treatment strategy. The primary objective is to establish whether a new VT ablation based on NIPS inducibility will reduce the risk of VT recurrence compared to antiarrhythmic drug therapy.",[27],[188],"Ventricular Tachycardia, VT, Non-Invasive Programmed Stimulation, NIPS, ICD, Implantable Cardioverter Defibrillator",{"date":190,"type":43},"2026-03-27",{"date":192,"type":43},"2025-06-12",{"date":194,"type":21},"2027-12",{"name":196,"class":81},"IRCCS Ospedale San Raffaele",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100619774","predicting-severe-cardiac-arrhythmias-in-the-perioperative-period-using-ai-ecg-100619774","NCT07348991","Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG","Predicting Atrial Fibrillation and Life-threatening Cardiac Arrhythmias and Conduction Disorders in the Perioperative Period in High Cardiac Risk Surgery Using Artificial Intelligence Elements","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Scheduled surgery with high cardiac risk\n* Informed consent was given to participate in the study\n\nExclusion Criteria:\n\n* Cancellation of the surgery for any reason;\n* The patient's unwillingness to continue participating in the study;\n* Poor quality of the ECG recording on a single-channel ECG monitor.",{"count":205,"type":21},300,"During the preoperative examination, in addition to the standard examination recommended before high-risk cardiac surgeries, a digital single-lead ECG is recorded using portable CardioQUARK devices. This ECG is analyzed for time, amplitude, and frequency parameters-more than 200 parameters per cardiac cycle. Additionally, the available parameters of a standard 12-lead ECG recording are determined. All parameters of both single-lead and 12-lead ECGs will be included in a multivariate regression analysis to determine the optimal method for predicting atrial fibrillation, life-threatening cardiac arrhythmias, and conduction abnormalities in the perioperative period after high-risk cardiac procedures.\n\nThe study will include patients undergoing high-risk cardiac surgeries, such as those on the heart, aorta, esophagus, pancreas, liver, and lungs, as well as high-risk oncological surgeries. A partial analysis will also be performed depending on the type of intervention. Rhythm and conduction disturbances will be recorded during surgery, as well as in the postoperative period, using ECG monitors, 24-hour ECG monitoring, and repeated recordings of a standard ECG when complaints or signs of unstable hemodynamics arise",[208,209,210,27,93],"Atrial Fibrillation","Atrioventricular Block, Second and Third Degree","Sinus Node Dysfunction",[212,213,214,215,216,217],"Electrocardiogram","Artificial intelligence","Cardiac arrhythmias","Atrioventricular block","Perioperative","Atrial fibrillation","2026-02-09",{"date":220,"type":43},"2026-02-10",{"date":222,"type":21},"2026-12-31",{"date":224,"type":21},"2028-05-30",{"name":226,"class":81},"I.M. Sechenov First Moscow State Medical University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":236,"studyType":63,"phases":4,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":129},"100608024","electrophysiological-registry-duesseldorf-100608024","NCT07196176","Electrophysiological Registry Duesseldorf","Registry on Electrophysiological Studies (EPS) at University Hospital Düsseldorf","Inclusion Criteria:\n\n* Patients who undergo an electrophysiological study (EPS) or electrical cardioversion at University Hospital Düsseldorf since 2015 (retrospective cohort)\n* Patients scheduled to undergo an EPS or electrical cardioversion at University Hospital Düsseldorf from 2019 onward (prospective cohort) •- Written informed consent for participation in the registry (prospective part only)\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Lack of written informed consent\n* Pregnancy",{"count":235,"type":21},1000,"2 Years","This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.",[66,239,240,27],"Atrial Flutter","Supraventricular Tachycardias",[68,242,243],"catheter ablation","cardioversion","2025-09-26",{"date":246,"type":43},"2025-09-29",{"date":248,"type":43},"2019-06-01",{"date":250,"type":21},"2031-12-31",{"name":252,"class":81},"Heinrich-Heine University, Duesseldorf",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":129},"100451457","myocarditis-causing-premature-ventricular-contractionsinsights-from-the-maveric-registry-100451457","NCT05158751","Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry","MAVERIC","Inclusion Criteria:\n\n* Patients \\> 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours.\n* Non-sustained VT was defined as ≥3 more consecutive beats lasting \\\u003C30 seconds\n\nExclusion Criteria:\n\n* History of myocardial infarction,\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography,\n* History of revascularization,\n* Significant symptomatic atrial arrhythmias associated with LV dysfunction,\n* Severe valvular disease,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs,\n* History of cardiac arrest,\n* History of channelopathies or inherited arrhythmias.",{"count":261,"type":21},100,"To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.",[264,265,27],"Myocarditis","Premature Ventricular Contractions","2025-08-27",{"date":268,"type":43},"2025-09-04",{"date":270,"type":21},"2026-01",{"date":272,"type":21},"2026-05",{"name":274,"class":81},"Kansas City Heart Rhythm Research Foundation",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":63,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100604452","ventricular-tachycardia-cohort-100604452","NCT07149701","Ventricular Tachycardia Cohort","Inclusion Criteria:\n\n* Sustained ventricular tachycardia (VT), defined as VT lasting ≥30 seconds or requiring intervention due to hemodynamic compromise within 30 seconds; or Clinically significant non-sustained VT (NSVT) where the treating clinician has determined that therapeutic intervention is necessary.\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional clinical trial that, in the judgment of the investigator, could interfere with the data collection or outcome assessment of this observational study.",{"count":282,"type":21},1500,"8 Years","The goal of this observational study is to detect the long-term risk of a composite endpoint event in adult patients with ventricular tachycardia (VT) who are managed with catheter ablation or non-ablation management (including modern drug therapy and\u002For ICD therapy).",[27],"2025-08-24",{"date":288,"type":43},"2025-09-02",{"date":290,"type":21},"2025-09-01",{"date":292,"type":21},"2029-12-01",{"name":80,"class":81},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100599078","clinical-study-on-the-efficiency-of-rapid-arrhythmia-mapping-using-easystars-high-density-mapping-catheter-applications-100599078","NCT07079813","Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","Rapid Arrhythm","1. Clinical diagnosis: Ventricular tachycardia (VT)\n\n   * Inclusion criteria:\n\n     1. Patients aged between 18 and 80 years;\n     2. Confirmed diagnosis of ventricular tachycardia (VT) via electrocardiogram (ECG) or 24-hour Holter monitoring;\n     3. The patient has experienced at least one episode of VT in the past 6 months and exhibits symptoms of sustained or paroxysmal ventricular tachycardia;\n     4. The patient meets the criteria for ablation surgery and has clear indications for ablation;\n     5. The patient is in good general health and able to tolerate surgery (no severe underlying heart disease, such as severe heart failure or severe coronary artery disease);\n     6. Voluntarily participates and signs an informed consent form.\n   * Exclusion criteria:\n\n     1. Uncontrolled heart failure (New York Heart Association functional class III-IV);\n     2. History of acute or progressive myocardial infarction;\n     3. Severe pulmonary, hepatic, or renal disease;\n     4. Valvular heart disease or congenital heart disease;\n     5. Excessive use of medications or medication intolerance (e.g., beta-blockers, antiarrhythmic drugs);\n2. Clinical diagnosis: Atrial tachycardia (AT)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with atrial tachycardia (AT) by electrocardiogram (ECG) or Holter monitoring;\n     3. Patients presenting with clinical symptoms such as palpitations, chest tightness, or fatigue;\n     4. Patients diagnosed with persistent or paroxysmal atrial tachycardia and meeting the criteria for ablation therapy;\n     5. Patients who voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease or congenital heart disease;\n     2. Patients with severe left ventricular or right ventricular heart failure;\n     3. Patients with severe systemic diseases, such as liver failure, kidney failure, or tumours;\n     4. Patients with cardiomyopathy or aortic dissection;\n3. Clinical diagnosis: atypical atrial flutter (AFL)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Patients diagnosed with atypical atrial flutter (AFL) via electrocardiogram (ECG) or Holter monitoring;\n     3. Patients with clinical symptoms (e.g., palpitations, chest tightness, fatigue, etc.) that significantly impair their quality of life;\n     4. Patients who meet the criteria for atrial tachycardia ablation and have no other severe comorbidities;\n     5. Voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe heart disease, such as cardiomyopathy or severe valvular disease;\n     2. Patients with severe pulmonary disease, such as pulmonary arterial hypertension;\n     3. Patients with a history of major cardiac surgery (e.g., heart transplantation);\n4. Clinically diagnosed with paroxysmal atrial fibrillation (PAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with paroxysmal atrial fibrillation (PAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Frequent episodes of paroxysmal atrial fibrillation with symptoms such as palpitations, fatigue, and dyspnoea, and meeting the criteria for ablation;\n     4. No other severe cardiac or systemic diseases, and meeting the criteria for ablation;\n     5. Voluntarily participating and signing the informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease, aortic dissection, or cardiomyopathy;\n     2. High-risk patients with a history of anticoagulant therapy or currently receiving anticoagulant therapy (e.g., history of thrombosis or stroke);\n     3. Patients with severe underlying conditions such as cancer or severe diabetes;\n5. Clinical diagnosis: Persistent atrial fibrillation (PsAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with persistent atrial fibrillation (PsAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Atrial fibrillation persisting for more than 7 days and symptoms affecting the patient's quality of life;\n     4. Clear indications for ablation and no other severe comorbidities;\n     5. Voluntarily participating and signing an informed consent form.\n\nExclusion criteria:\n\n1. Presence of severe valvular heart disease or cardiomyopathy;\n2. History of stroke or clinical evidence of thrombus formation;\n3. Severe heart failure (NYHA III-IV class);\n4. High-risk cardiac conditions (e.g., acute myocardial infarction, coronary artery disease); In the above different types of rapid arrhythmias, the inclusion criteria primarily focus on the diagnosis and control of clinical symptoms for different types of arrhythmias, while the exclusion criteria focus on avoiding patients with severe comorbidities or those unable to tolerate surgery. Through this patient screening method, the safety of the study and the accuracy of the data are ensured, thereby enabling a better assessment of the clinical efficacy of the new EasyStars catheter.","80 Years",{"count":205,"type":21},[24],"The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.",[27,306,307,308],"Atrial Tachycardia","Typical Atrial Flutter","Paroxysmal Atrial Fibrillation (PAF)","2025-07-28",{"date":311,"type":43},"2025-07-31",{"date":313,"type":21},"2025-08-30",{"date":315,"type":21},"2027-12-31",{"name":317,"class":50},"Shanghai MicroPort EP MedTech Co., Ltd.",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":129},"100594995","transcutaneous-vagus-nerve-stimulation-for-ventricular-arrhythmias-100594995","NCT07026695","Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias","Transcutaneous Electrical Vagus Nerve Stimulation for Suppression of Ventricular Arrhythmias","TREAT-VT","PVC Cohort\n\nInclusion Criteria:\n\n* Age \\> 18 years old.\n* Participants must understand and be willing to sign a written informed consent document.\n* PVC burden of \\>10% in a 24-hour period on Holter monitoring.\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Known cardiac disease (heart failure or cardiomyopathy) in the documented absence of PVCs. Individuals with suspected PVC-induced cardiomyopathy heart failure, defined as cardiomyopathy or heart failure only diagnosed in the setting of a \\>10% PVC burden, will be allowed to participate.\n* A known diagnosis of Epilepsy.\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication\n\nVT cohort\n\nInclusion Criteria:\n\n* Participants with structural heart disease and a transvenous implantable cardioverter defibrillator (ICD) in situ\n* At least three clinically significant VT events (VT events defined as either \\>30 seconds of sustained VT, appropriate ICD ATP therapies or appropriate ICD shocks) in the six months before enrolment\n\nExclusion Criteria:\n\n* Heart failure syndrome with inotrope dependency or requiring mechanical assistance.\n* Reversible cause of arrhythmia (e.g. culprit electrolyte abnormality or toxin)\n* NYHA (New York Heart Association) stage IV heart failure\n* Myocardial infarction or cardiac surgery in the last six months\n* Life expectancy \\\u003C12 months\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication",{"count":327,"type":21},72,[24],"Ventricular arrhythmias are abnormal heart rhythms that arise from the bottom chambers of the heart. They can cause debilitating symptoms when they occur intermittently (these are called premature ventricular ectopics or PVCs) and can be life-threatening when they occur continuously (called ventricular tachycardia or VT). These are the most common causes of sudden cardiac death, especially in patients with pre-existing heart disease.\n\nThey can be a result of overactivation of the sympathetic nervous system, and in extreme circumstances, surgery to cut the nerve may be needed. A novel approach to target this nervous system using a transcutaneous electrical nerve stimulator (TENS) machine has successfully treated arrhythmias that come from the top chambers of the heart (atrial fibrillation). An ear clip is applied for an hour per day connected to a device (smaller than a phone) that can activate the parasympathetic nervous system (that counteracts the sympathetic nervous system). This is called Low-Level Tragus Stimulation (LLTS). Because it has been used for epilepsy for decades, we have evidence of a very high safety profile and tolerability. We plan to enrol 72 patients, 34 with many PVCs and 38 with VT, and randomise them to either first receive LLTS or first receive sham treatment (this will appear the same to the patient and researchers but without any meaningful vibrations being emitted in the sham group). Each patient will then swap over to the other treatment. We will compare whether the LLTS reduces the amount of ventricular arrhythmias during compared to the amount during the sham treatment period. We will use Holter monitors to measure the amount of PVCs after each period in the PVC group. VT patients have an implantable defibrillator that continuously monitors for VT episodes in this group. We will only enrol adults who can give informed consent, and study participation will not interfere with a patient's clinical treatment.",[331,27,332],"Premature Ventricular Complexes","Ventricular Arrhythmias",[334,335,336,337,338],"double-blinded","randomized","sham-controlled","crossover","prospective","2025-06-18",{"date":341,"type":43},"2025-06-24",{"date":343,"type":21},"2025-06-15",{"date":315,"type":21},{"name":346,"class":81},"University College, London",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":366,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":129},"100594316","stereotactic-radiosurgery-as-second-line-therapy-for-ventricular-tachycardia-100594316","NCT07017855","Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia","STAR-4VT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of enrollment.\n2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.\n3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).\n4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.\n5. Recurrence of at least one clinically significant and symptomatic episode of monomorphic sVT.\n6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.\n7. Provision of written informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).\n2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.\n3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.\n4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.\n5. Acute decompensation of heart failure, classified as New York Heart Association (NYHA) Class IV, until clinical stabilization is achieved.\n6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.\n7. A mobile thrombus within the left ventricle (LV).\n8. Presence of a left ventricular assist device (LVAD).\n9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a contraindication to the procedure for safety reasons.\n10. Active, uncontrolled malignancy and\u002For chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.\n11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, corticosteroids, immunosuppressants) within the past 6 months.\n12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.\n13. Pregnancy or breastfeeding.\n14. Systemic disease that limits the probability of survival to less than 1 year\n15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.\n16. Refusal to participate or lack of written informed consent for study participation.",{"count":355,"type":21},150,[24],"The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).",[359,360,27,361,362,363,364,365],"Ventricular Tachycardia, Monomorphic","Ventricular Tachycardia, Sustained","Ventricular Tachycardia (V-Tach)","Stereotactic Body Radiation Therapy (SBRT)","Stereotactic Techniques","Stereotactic Radiation","Cardioverter-Defibrillators, Implantable",[118,367,368,143,369,370],"VT","Stereotactic Arrhythmia Radioablation","Implanted Cardioverter-Defibrillator","ICD","2025-06-04",{"date":192,"type":43},{"date":374,"type":21},"2025-07-01",{"date":376,"type":21},"2028-11-01",{"name":378,"class":81},"Medical University of Silesia"]